Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-30355 in Advanced Solid Tumors With TP53 Y220C Mutation
NCT06386146Phase 2Recruiting
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of JAB-30355 (Jacobio Pharma) in solid tumor, sponsored by Jacobio Pharmaceuticals. Started Jul 2024; status: recruiting.
02
Drugs
JAB-30355 (Jacobio Pharma)
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06386146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06386146.